ML-007C-MA
Asset
Combines central M1 and M4 muscarinic receptor agonism with peripheral muscarinic antagonism to limit peripheral side effects.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Not known
- 1
- Indication
- 2
- Trials
- 1
- Developer
Indications
1Psychosis associated with Alzheimer's disease
Phase 2, Recruiting, NCT06887192, clinicaltrials.gov, Oct 31, 2026
In the full profile
- Owner and partners1
- Trials2
- Competitors1
- Signals4
Every asset’s record: target, stage, trials and the evidence behind it.